FY2024 EPS Forecast for Dyne Therapeutics Lowered by Analyst

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at HC Wainwright lowered their FY2024 earnings per share estimates for Dyne Therapeutics in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($3.55) per share for the year, down from their previous forecast of ($3.06). HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.39) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2024 earnings at ($1.04) EPS, FY2025 earnings at ($3.35) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at $0.19 EPS.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25).

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $43.00 to $35.00 in a report on Thursday, October 24th. StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Piper Sandler reissued an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Oppenheimer restated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $29.68 on Monday. The firm has a market capitalization of $3.02 billion, a P/E ratio of -8.34 and a beta of 1.10. Dyne Therapeutics has a one year low of $10.03 and a one year high of $47.45. The company’s 50-day simple moving average is $32.36 and its 200 day simple moving average is $35.29.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. This represents a 25.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carlo Incerti sold 16,500 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 176,257 shares of company stock valued at $6,193,718. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DYN. Nisa Investment Advisors LLC grew its stake in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the period. Quantbot Technologies LP purchased a new position in Dyne Therapeutics during the third quarter valued at approximately $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics in the third quarter worth approximately $36,000. US Bancorp DE increased its stake in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $62,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.